Furthermore, KIF18A expression was positively correlated with many common immune checkpoints, including PD-L1, PD-1, CTLA4, TIGIT, HAVCR2, PDCD1LG2, and LAG3, indicating that KIF18A may be a new target for tumor immunotherapy. This evidence concerns the gene HAVCR2 and neoplasm.